Australia’s largest in vitro fertilization (IVF) provider, ASX-listed Virtus Health, is the target of a buyout from European PE firm CapVest. CapVest is offering A$7.60 per share for Virtus. Virtus has granted CapVest exclusive due diligence rights. The CapVest proposal outstrips that of Australian PE firm, BGH Capital, which made a bid for the company…
Home Healthcare Markets International News Australia: CapVest trumps BGH proposal in bid in for Virtus Health